



You are being prescribed Ivermectin off-label for a positive COVID-19 test result, symptoms of COVID-19 with known exposure, or prophylactically for known exposure to someone with a positive COVID-19 test result.

I am prescribing based upon the The Front Line Covid-19 Critical Care Alliance (FLCCC Alliance) I-MASK+ protocol. This protocol is based upon the data and the studies showing reduced number of cases of positive COVID19 in healthcare workers and family members in the same household with a person who tested positive for COVID-19 (1,2,3). Or, data showing shorter duration of symptoms, faster discharge from the hospitals, and reduced number of deaths due to COVID-19. (4, 5, 6, 7).

However, even when your symptoms have improved or you avoid symptoms all together it is imperative you continue to exercise social distancing and standard precautions such as face mask, hand washing, etc.

This is not to be considered a cure or prevention. I highly encourage you to visit <https://covid19criticalcare.com/network-support/patients-and-relatives/> for more tools, information, and recommendations.

The information below is taken from the FLCCC Alliance website.

In our opinion, the following precautions are indispensable for prophylaxis against infection with the SARS-CoV-2 virus:

- Wear Masks. Must wear cloth, surgical, or N95 mask (without valve) in all indoor spaces with non-household persons. Must wear a N95 mask (without valve) during prolonged exposure to non-household persons in any confined, poorly ventilated area.
- Keep distance. Until the end of the Covid-19 crisis, we recommend keeping a minimum distance of approx. 2m/6 feet in public from people who are not from your own household.
- Wash hands. We recommend, after a stay during and after outings from home (shopping, subway etc.), a thorough hand cleaning (20–30 sec. with soap), or also to use a hand disinfectant in between.

Useful links

The World Health Organization (WHO) has collected useful information for the public on their website, as:

- [Coronavirus disease \(COVID-19\) advice for the public](#)
- [When and how to use masks](#)
- [Q&As on COVID-19 and related health topics](#)
- [COVID-19: Mythbusters](#)

Short info on our COVID-19 protocols

The Front Line Covid-19 Critical Care Alliance has recently developed a prophylactic and early outpatient combination treatment protocol for COVID-19 called I-Mask+. This protocol is centered around the use of Ivermectin, a well-known anti-parasite drug with recently discovered anti-viral and anti-inflammatory properties and a rapidly growing published medical evidence base demonstrating its unique and highly potent ability to inhibit SARS-CoV-2 replication. Please do not use this protocol on your own without first consulting your family doctor.

- The I-MASK+ Prophylaxis & Early Outpatient Treatment Protocol for COVID-19 can be downloaded [here](#) (PDF)
- A concise summary of the longer scientific review manuscript below can be downloaded [here](#) (PDF, continuously updated)
- An introductory video further explaining the rationale by Dr. Pierre Kory can be found [here](#) (Vimeo)
- Paul Marik's recent lecture on I-MASK+ is found [here](#) (YouTube)

In March, 2020 we first published our [MATH+ Hospital Treatment Protocol for Covid-19](#), intended for hospitalized patients. The recently developed [I-MASK+ Prophylaxis & Early Outpatient Treatment Protocol for COVID-19](#) is instead directed for use as a prophylaxis and in early outpatient treatment after contracting COVID-19. The protocols thus complement each other, and both are physiologic-based combination treatment regimens developed by



leaders in critical care medicine. All component medicines are FDA-approved, inexpensive, readily available and have been used for decades with well-established safety profiles.

<https://covid19criticalcare.com/network-support/patients-and-relatives/>

References:

November 16, 2020 | Egypt

1. [Efficacy and safety of ivermectin for treatment and prophylaxis of COVID-19 pandemic.](#)

Elgazzar A, Basma H, Shaimaa Abo Y, Basma H, Mohy H, Hany M (Research Square; 100956). <https://doi.org/10.21203/rs.3.rs-100956/v2>

October 27, 2020 | Iran

2. Controlled randomized clinical trial on using ivermectin with doxycycline for treating COVID-19 patients in Baghdad, Iraq. Hashim HA, Maulood MF, Rasheed AM, Fatak DF, Kabah KK, Abdulmir AS (medRxiv). <https://doi.org/10.1101/2020.10.26.20219345>

June 9, 2020 | Egypt

3. Prophylactic Ivermectin in COVID-19 Contacts. Waheed Shouman, Zagazig University (ClinicalTrials.gov; NCT04422561). <https://clinicaltrials.gov/ct2/show/NCT04422561>

June 2020 | Australia

4. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM (Antiviral Res.; 178:104787). <https://doi.org/10.1016/j.antiviral.2020.104787>

August 24, 2020 | Bangladesh

5. Clinical trial of ivermectin plus doxycycline for the treatment of COVID-19 infection. Dr. Reaz Mahmud, Dhaka Medical College (ClinicalTrials.gov; NCT04523831). <https://clinicaltrials.gov/ct2/show/NCT04523831>

October 2020 | Peru

6. Real-world evidence: The case of Peru. Causality between ivermectin and COVID-19 infection fatality rate. Juan Chamie (ResearchGate). https://www.researchgate.net/publication/344469305_Real-World_Evidence_The_Case_of_Peru_Causality_between_Ivermectin_and_COVID-19_Infection_Fatality_Rate

October 12, 2020 | USA

7. Use of ivermectin is associated with lower mortality in hospitalized patients with COVID-19. Rajter J-C, Sherman MS, Fatteh N, Vogel F, Sacks J, Rajter J-J (ICON study; Chest). <https://doi.org/10.1016/j.chest.2020.10.009>.